Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 9/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29703 | 0.87 | LMNA (0.49) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL1062447 | 0.87 | LMNA (0.49) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL29446054 | 0.87 | LMNA (0.49) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL14084325 | 0.87 | LMNA (0.49) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL14534827 | 0.87 | LMNA (0.49) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL11940587 | 0.84 | SLC6A2 (0.35) | CYP1A2ALDH1A1 | |
| SCHEMBL14454732 | 0.84 | SLC6A2 (0.35) | CYP1A2ALDH1A1 | |
| SCHEMBL11934657 | 0.81 | SLC29A1 (0.42) | SLC29A1ADORA3 | |
| SCHEMBL11934656 | 0.81 | SLC29A1 (0.42) | SLC29A1ADORA3 | |
| SCHEMBL11934654 | 0.80 | SLC6A2 (0.33) | CYP1A2NFKB1THPOALDH1A1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123993-A1 | SELECTIVE APOPTOSIS-INDUCING METHODS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-111849912-B | Method for activating T cells using inducible chimeric polypeptides | 贝里坤制药股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11839647-B2 | Methods for inducing partial apoptosis using caspase polypeptides | BELLICUM PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230270831-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BAYLOR COLLEGE OF MEDICINE | 2023-08-31 | — | — | US | disclosed |
| EP-4219544-A1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum (NL) | 2023-08-02 | — | — | EP | disclosed |
| EP-4201955-A1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum (NL) | 2023-06-28 | — | — | EP | disclosed |
| US-20230065562-A1 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-03-02 | — | — | US | disclosed |
| EP-3268014-B1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | ACADEMISCH ZIEKENHUIS LEIDEN H O D N LEIDS UNIV MEDISCH CENTRUM (NL) | 2022-09-21 | — | — | EP | disclosed |
| US-20220125837-A1 | METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-04-28 | — | — | US | disclosed |
| US-20220025024-A1 | METHODS FOR ACTIVATING T CELLS USING AN INDUCIBLE CHIMERIC POLYPEPTIDE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-7632932-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579451-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090156529-A1 | RNAi Inhibition of Alpha-ENaC Expression | NOVARTIS AG | 2009-06-18 | — | — | US | disclosed |
| EP-1913011-A2 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | Alnylam Pharmaceuticals Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20070197460-A1 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2006112872-A2 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197460-A1 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | SNRPE, EIF2AK2, AGO2 | CYP1A2 4676/4885NFKB1 2845/4885THPO 4413/4885 |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | DUT, NOP58, DPYD | CYP1A2 4506/4885NFKB1 1153/4885THPO 1513/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | CYP1A2 4285/4885NFKB1 944/4885THPO 1984/4885 |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | NT5C3B, DERA, DUT | CYP1A2 4739/4885NFKB1 1051/4885THPO 1965/4885 |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | NT5C3B, DERA, DUT | CYP1A2 4739/4885NFKB1 1051/4885THPO 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.